Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS

201867 citationsJournal Articlegold Open Access

Authors

Stephen A. Goutman · University of Michigan–Ann Arbor

Morton B. Brown · University of Michigan–Ann Arbor

Jonathan D. Glass · Emory University

Nicholas M. Boulis · Woodruff Health Sciences Center

Karl Johe · Intelligent Fusion Technology (United States)

Tom Hazel · Neural Signals (United States)

Merit Cudkowicz

Abstract

Comparison of Ph1/2 studies to historical datasets revealed significantly improved survival and function using ALS/SURV versus PRO-ACT controls. While results are encouraging, comparison against historical populations demonstrate limitations in noncontrolled studies. These findings support continued evaluation of HSSC transplantation in ALS, support the benefit of control populations, and enable necessary power calculations to design a randomized, sham surgery-controlled efficacy study.

Topics & Keywords

Amyotrophic Lateral Sclerosis Research Neurogenetic and Muscular Disorders Research

Publication Details

Published in: Annals of Clinical and Translational Neurology

Volume 5, Issue 6, pp. 730-740

DOI: 10.1002/acn3.567

Field-Weighted Citation Impact: 5.61

Command Palette

Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS

Authors

Abstract

Topics & Keywords

Publication Details